Shares of Gelteq Ltd (NASDAQ:GELS) rose sharply in pre-market trading after the company reported positive preclinical results for its cannabinoid oral gel delivery platform. The Melbourne-based company reported that its proprietary oral gel platform achieved a greater than 22% increase in the…
Continue reading...